샘플 요청 목록

 카트 문의
시장보고서
상품코드
1793756

세계의 폐섬유증 치료 시장

Pulmonary Fibrosis Treatment
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 376 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

폐섬유증 치료 세계 시장은 2030년까지 42억 달러에 달할 전망

2024년에 32억 달러로 추정되는 폐섬유증 치료 세계 시장은 2024-2030년 분석 기간에 CAGR 5.0%로 성장하여 2030년에는 42억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 단독요법은 CAGR 5.6%를 기록하며 분석 기간 종료시에는 27억 달러에 달할 것으로 예측됩니다. 병용요법 부문의 성장률은 분석 기간 동안 CAGR 4.2%로 추정됩니다.

미국 시장은 8억 5,970만 달러로 추정, 중국은 CAGR 9.1%로 성장 예측

미국의 폐섬유증 치료 시장은 2024년에 8억 5,970만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 8억 9,480만 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 9.1%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 2.0%와 3.9%로 예측됩니다. 유럽에서는 독일이 CAGR 3.0%로 성장할 것으로 예측됩니다.

세계의 폐섬유증 치료 시장 - 주요 동향과 촉진요인 정리

폐섬유증이 호흡기 치료제의 최우선 타겟으로 떠오르고 있는 이유는 무엇일까?

폐섬유증, 특히 특발성 폐섬유증(IPF)은 진행성, 비가역성, 장기적인 예후가 좋지 않아 제약회사 및 의료계의 관심이 높아지고 있습니다. 이 질환은 폐조직의 흉터가 특징이며, 폐 기능, 운동 능력, 생존율이 꾸준히 감소하는 것이 특징입니다. IPF의 평균 생존기간은 진단 후 3-5년이며, 치료법의 혁신은 역사적으로 제한적이었습니다. 그러나 진단 인식의 향상, 첨단 영상 진단, 바이오마커를 이용한 계층화 등으로 조기 개입이 가능해져 치료 가능한 환자군이 확대되고 있습니다.

IPF 및 기타 섬유성 간질성 폐질환(ILDs)은 고령화, 환경 노출, 류마티스 관절염 및 전신성 경화증과 같은 동반 질환으로 인해 전 세계적으로 그 부담이 증가하고 있습니다. 섬유화 메커니즘에 대한 이해도가 높아짐에 따라 폐 기능 저하를 늦추기 위해 항섬유화 요법을 질병 경과 초기에 시작해야 한다는 공감대가 형성되고 있습니다. 이 때문에 미국 흉부학회(ATS)와 같은 단체의 가이드라인이 발전하여 일상적인 폐 기능 모니터링과 치료제에 대한 조기 접근을 옹호하고 있습니다. 그 결과, 치료법은 대증요법에서 질병 변형 치료로 전환되고 있습니다.

시장 개척을 형성하고 있는 약제 클래스별, 신규 기전별, 환자층은?

현재 치료의 주류는 피르페니돈(에스브리트)과 닌테다닙(오페브)의 두 가지 항섬유화제입니다. 두 약제는 미국, EU, 아시아태평양에서 IPF 치료제로 승인되었으며, 강제폐활량(FVC) 감소를 지연시키는 효과가 입증되었습니다. 피르페니돈은 경구용 피리돈계 화합물로 TGF-β&를 비롯한 섬유화 사이토카인을 억제하여 항염증 작용과 항섬유화 작용을 발휘합니다. 티로신 키나아제 억제제인 닌테다닙은 PDGF, FGF, VEGF 등의 경로를 표적으로 삼습니다. 두 약물 모두 소화기 부작용이 있어 장기적인 순응도가 필요하지만, 대부분의 고소득 국가에서는 여전히 표준 치료법으로 사용되고 있습니다.

닌테다닙은 IPF뿐만 아니라 진행성 섬유성 ILD, 전신성 경화증 관련 ILD까지 적응증을 확대하고 있습니다. 이는 여러 섬유화 병태에 대한 항섬유화 약물의 포지셔닝을 변경하는 보다 광범위한 추세를 반영합니다. 현재 임상시험에서는 항섬유화제 및 면역조절제, 항세포인자 요법, 항노화제 등의 병용요법이 시험되고 있습니다. PLN-74809(Pliant Therapeutics의 듀얼 인테그린 억제제)와 PRM-151(ziltivekimab)과 같은 표적 분자는 섬유아세포의 활성화와 ECM 리모델링을 억제하는 목적으로 개발 중입니다. 소아 섬유성 폐질환, 코로나 이후 폐섬유증과 같은 희귀 환자 코호트도 파이프라인 다각화 전략에서 주목받고 있습니다.

진단, 디지털 도구, 임상 가이드라인은 치료의 보급과 최적화에 어떤 영향을 미치고 있는가?

고해상도 컴퓨터 단층촬영(HRCT), 폐 생검 기술, 디지털 청진 도구의 개선으로 진단의 정확도가 향상되고, 섬유증의 하위 유형에 대한 계층화가 가능해졌습니다. 과민성 폐렴이나 비특이적 간질성 폐렴과 같은 다른 ILD와 IPF를 구별하는 능력은 치료의 차이를 고려할 때 매우 중요합니다. HRCT에서 일반적인 간질성 폐렴(UIP)과 같은 패턴을 진단하기 위한 보조 수단으로 AI를 활용한 이미지 분석 및 머신러닝 툴이 등장하고 있으며, 치료 적격성 및 시험 모집에 정보를 제공할 수 있습니다.

원격의료 플랫폼과 디지털 흡입 순응도 도구는 특히 원격지나 의료 서비스가 부족한 지역의 환자들을 대상으로 만성질환 관리를 돕고 있습니다. 환자 보고 결과 측정(PROM)과 모바일 척추측만술은 종단적 모니터링의 틀에 점점 더 통합되고 있으며, 임상의가 환자의 기능 및 진행 속도에 따라 치료 요법을 조정할 수 있도록 돕고 있습니다. ATS, ERS, NICE 등의 단체의 가이드라인에서는 현재 다학제적 논의(MDD)와 3-6개월마다 정기적인 기능평가를 강조하고 있으며, 이를 통해 치료 조정과 적시 에스컬레이션을 용이하게 하고 있습니다.

세계 폐섬유증 치료 시장의 성장을 촉진하는 요인은 무엇인가?

세계 폐섬유증 치료 시장의 성장은 질병 유병률 증가, 항섬유화 치료의 적응증 확대, 여러 섬유성 ILD 아형에 걸친 탄탄한 파이프라인 혁신에 의해 주도되고 있습니다. 또한, 미국, EU, 일본의 높은 미충족 임상 수요, 희귀질환 치료제(희귀의약품) 특혜, 약사법 규제 신속화 등으로 제약기업의 관심이 높아지고 있습니다. 헬스케어 시스템이 호흡기 내과 네트워크를 통해 조기 발견에 익숙해지면 진단 및 치료 대상이 크게 확대될 것으로 예상됩니다.

또한, 생명공학기업과 대형 제약사와의 전략적 제휴, 라이선싱 계약, 인수를 통해 임상 개발이 가속화되고 있습니다. 실제 임상적 근거가 시장 진입 및 가격 전략에 반영되는 경향이 강화되고 있으며, 신흥 시장에서도 고가의 항섬유화제가 더 광범위하게 급여화되는 추세입니다. 지역적으로는 북미와 서유럽이 진단 및 치료법 보급에 있어 선두를 달리고 있지만, 아시아태평양 시장은 인지도 향상과 상환 정책의 진화로 인해 빠르게 성장하고 있습니다.

주요 시장 진입 기업으로는 로슈, 베링거인겔하임, 파이브로젠, 프라이언트 테라퓨틱스, 갈라파고스 NV, 벨레로폰 테라퓨틱스, 유나이티드 테라퓨틱스 등이 있습니다. 차세대 섬유증 치료제 및 동반진단 약물의 등장이 예상됨에 따라, 이 시장은 정밀 치료, 조기 치료 시작, 전인적 환자 관리 모델을 중심으로 장기적인 성장이 예상됩니다.

부문

치료 유형(단독요법, 병용요법, 대증요법), 적응증(특발성 폐섬유증, 가족성 PF, 기타 적응증), 유통 채널(병원 약국, 소매 약국, 통신판매 약국 유통 채널)

조사 대상 기업 사례

  • AstraZeneca PLC
  • Avalyn Pharma Inc.
  • Biogen Inc.
  • Boehringer Ingelheim
  • Bristol-Myers Squibb Company
  • Cipla Inc.
  • FibroGen, Inc.
  • Galapagos NV
  • Genentech(Roche)
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • MediciNova, Inc.
  • Medtronic plc
  • Merck & Co., Inc.
  • Novartis AG
  • Pliant Therapeutics Inc.
  • Promedior, Inc.
  • Roche Holding AG
  • United Therapeutics Corporation
  • Vicore Pharma AB

AI 통합

우리는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범을 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 25.08.26

Global Pulmonary Fibrosis Treatment Market to Reach US$4.2 Billion by 2030

The global market for Pulmonary Fibrosis Treatment estimated at US$3.2 Billion in the year 2024, is expected to reach US$4.2 Billion by 2030, growing at a CAGR of 5.0% over the analysis period 2024-2030. Monotherapy, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$2.7 Billion by the end of the analysis period. Growth in the Combination Therapy segment is estimated at 4.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$859.7 Million While China is Forecast to Grow at 9.1% CAGR

The Pulmonary Fibrosis Treatment market in the U.S. is estimated at US$859.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$894.8 Million by the year 2030 trailing a CAGR of 9.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.0% and 3.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.0% CAGR.

Global Pulmonary Fibrosis Treatment Market - Key Trends & Drivers Summarized

Why Is Pulmonary Fibrosis Emerging as a High-Priority Target in Respiratory Therapeutics?

Pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF), has drawn increasing focus from pharmaceutical developers and healthcare systems due to its progressive, irreversible nature and poor long-term prognosis. The disease is characterized by scarring of lung tissues, leading to a steady decline in lung function, exercise capacity, and ultimately survival. IPF has a median survival time of three to five years post-diagnosis, and therapeutic innovation has been historically limited. However, rising diagnostic awareness, advanced imaging modalities, and biomarker-led stratification are facilitating earlier intervention and expanding the treatment-eligible patient pool.

The global burden of IPF and other fibrotic interstitial lung diseases (ILDs) is increasing due to aging populations, environmental exposures, and comorbid conditions such as rheumatoid arthritis and systemic sclerosis. As understanding of fibrotic mechanisms improves, there is a growing consensus that antifibrotic therapies should be initiated earlier in the disease course to decelerate lung function loss. This has led to evolving guidelines by organizations such as the American Thoracic Society (ATS), advocating for routine pulmonary function monitoring and earlier access to therapeutic agents. As a result, the therapeutic landscape is transitioning from symptom management to disease-modifying interventions.

Which Drug Classes, Novel Mechanisms, and Patient Segments Are Shaping Market Development?

The current treatment landscape is dominated by two antifibrotic agents: pirfenidone (Esbriet) and nintedanib (Ofev). Both drugs received approval in the U.S., EU, and Asia-Pacific for IPF management and have demonstrated efficacy in slowing forced vital capacity (FVC) decline. Pirfenidone, an oral pyridone compound, exerts anti-inflammatory and antifibrotic effects by inhibiting TGF-β and other fibrogenic cytokines. Nintedanib, a tyrosine kinase inhibitor, targets pathways including PDGF, FGF, and VEGF. Both agents are associated with gastrointestinal side effects and require long-term compliance, yet remain the standard of care in most high-income countries.

Beyond IPF, nintedanib has gained expanded indication for progressive fibrosing ILDs and systemic sclerosis-associated ILD. This reflects a broader trend in repositioning antifibrotics for multiple fibrotic pathologies. Clinical trials are now testing combination regimens, including the pairing of antifibrotics with immunomodulators, anti-cytokine therapies, and senolytic agents. Targeted molecules such as PLN-74809 (a dual integrin inhibitor by Pliant Therapeutics) and PRM-151 (ziltivekimab) are under development with the aim to interrupt fibroblast activation and ECM remodeling. Rare patient cohorts, such as pediatric fibrotic lung disease and post-COVID pulmonary fibrosis, are also gaining attention in pipeline diversification strategies.

How Are Diagnostics, Digital Tools, and Clinical Guidelines Impacting Treatment Uptake and Optimization?

Improved high-resolution computed tomography (HRCT), lung biopsy techniques, and digital auscultation tools are enhancing diagnostic accuracy and enabling stratification of fibrosis subtypes. The ability to distinguish IPF from other ILDs-such as hypersensitivity pneumonitis and nonspecific interstitial pneumonia-is critical, given treatment differences. AI-powered imaging analysis and machine learning tools are emerging as aids in diagnosing patterns such as usual interstitial pneumonia (UIP) on HRCT, which can inform treatment eligibility and trial recruitment.

Telehealth platforms and digital inhaler adherence tools are supporting chronic disease management, especially for patients in remote or underserved areas. Patient-reported outcome measures (PROMs) and mobile spirometry are increasingly integrated into longitudinal monitoring frameworks, allowing clinicians to tailor treatment regimens based on patient functionality and progression speed. Guidelines from organizations such as ATS, ERS, and NICE now emphasize multidisciplinary discussions (MDDs) and routine functional assessment every 3-6 months, facilitating treatment adjustment and timely escalation.

What Factors Are Driving the Growth of the Global Pulmonary Fibrosis Treatment Market?

The growth in the global pulmonary fibrosis treatment market is driven by rising disease prevalence, expanding indications for antifibrotic therapies, and robust pipeline innovation across multiple fibrotic ILD subtypes. Pharmaceutical interest is further fueled by high unmet clinical needs, orphan drug incentives, and accelerated regulatory pathways in the U.S., EU, and Japan. As healthcare systems become more adept at early detection through pulmonology networks, the diagnosed and treated population base is expected to expand significantly.

Furthermore, strategic collaborations, licensing deals, and acquisitions between biotechs and large pharma players are facilitating faster clinical development. Real-world evidence is increasingly being incorporated into market access and pricing strategies, enabling broader reimbursement of high-cost antifibrotics in emerging markets. Geographically, North America and Western Europe continue to lead in terms of diagnosis and therapy adoption, but Asia-Pacific markets are seeing rapid growth due to increasing awareness and evolving reimbursement policies.

Major market participants include Roche, Boehringer Ingelheim, FibroGen, Pliant Therapeutics, Galapagos NV, Bellerophon Therapeutics, and United Therapeutics. With the anticipated arrival of next-generation fibrosis inhibitors and companion diagnostics, the market is poised for long-term growth centered on precision therapy, earlier treatment initiation, and holistic patient care models.

SCOPE OF STUDY:

The report analyzes the Pulmonary Fibrosis Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapy Type (Monotherapy, Combination Therapy, Symptomatic Treatment); Indication (Idiopathic Pulmonary Fibrosis, Familial PF, Other Indications); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Mail Order Pharmacy Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

  • AstraZeneca PLC
  • Avalyn Pharma Inc.
  • Biogen Inc.
  • Boehringer Ingelheim
  • Bristol-Myers Squibb Company
  • Cipla Inc.
  • FibroGen, Inc.
  • Galapagos NV
  • Genentech (Roche)
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • MediciNova, Inc.
  • Medtronic plc
  • Merck & Co., Inc.
  • Novartis AG
  • Pliant Therapeutics Inc.
  • Promedior, Inc.
  • Roche Holding AG
  • United Therapeutics Corporation
  • Vicore Pharma AB

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Pulmonary Fibrosis Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Idiopathic Pulmonary Fibrosis Drives Demand for Targeted Therapeutics
    • Advancements in Antifibrotic Drug Development Strengthen Business Case for New Entrants
    • Increased Clinical Research in Combination Therapies Expands Treatment Possibilities
    • Growth in Aging Population Throws the Spotlight on Fibrosis-Related Lung Disorders
    • Focus on Biomarker-Based Diagnosis Enhances Early Intervention Strategies
    • Expansion of Patient Access Programs in Emerging Markets Accelerates Drug Penetration
    • Regulatory Fast-Track Designations Propel Market Entry of Novel Therapeutics
    • Collaborations With Academic Institutions Foster Innovation in Pathogenesis Research
    • Rising Use of AI in Clinical Trials Enhances Drug Development Efficiency
    • Investment in Inhaled Therapy Delivery Systems Improves Patient Compliance
    • Increased Awareness Campaigns Drive Earlier Diagnosis and Therapeutic Uptake
    • Use of Digital Health Platforms Supports Monitoring of Long-Term Fibrosis Progression
    • Emergence of Precision Medicine Approaches Expands Addressable Patient Subsets
    • Integration of Genomic Insights Into Treatment Pathways Strengthens Personalization
    • Rising Focus on Rare Disease Therapeutics Promotes Investment in Fibrosis Pipelines
    • Government Incentives for Orphan Drug Development Strengthen R&D Funding Support
    • Entry Into Biosimilars and Generics Intensifies Market Competition
    • Availability of Multidisciplinary Care Models Improves Patient Treatment Continuity
    • Expansion of Lung Transplant Programs Sustains Demand for Pre- and Post-Therapy Drugs
    • OEM-Driven Expansion of Global Clinical Trial Networks Supports Regulatory Approval in New Regions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Pulmonary Fibrosis Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Pulmonary Fibrosis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Pulmonary Fibrosis Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Monotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Monotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Monotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Combination Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Combination Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Combination Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Symptomatic Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Symptomatic Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Symptomatic Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Idiopathic Pulmonary Fibrosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Idiopathic Pulmonary Fibrosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Familial PF by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Familial PF by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Familial PF by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Mail Order Pharmacy Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Mail Order Pharmacy Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Mail Order Pharmacy Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Pulmonary Fibrosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • JAPAN
    • Pulmonary Fibrosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • CHINA
    • Pulmonary Fibrosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: China 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: China 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: China 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • EUROPE
    • Pulmonary Fibrosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Pulmonary Fibrosis Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Pulmonary Fibrosis Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • FRANCE
    • Pulmonary Fibrosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: France 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: France 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: France 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • GERMANY
    • Pulmonary Fibrosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Germany 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Italy 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Pulmonary Fibrosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: UK 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: Spain 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: Spain 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Russia 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Russia 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Pulmonary Fibrosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Pulmonary Fibrosis Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 16-Year Perspective for Pulmonary Fibrosis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Pulmonary Fibrosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Australia 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Australia 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • INDIA
    • Pulmonary Fibrosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 164: India Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: India 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: India 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: India 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: South Korea 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: South Korea 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Pulmonary Fibrosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Pulmonary Fibrosis Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Latin America 16-Year Perspective for Pulmonary Fibrosis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Latin America 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Argentina 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Argentina 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Brazil 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 217: Brazil 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 223: Mexico 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 226: Mexico 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Pulmonary Fibrosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Pulmonary Fibrosis Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 241: Middle East 16-Year Perspective for Pulmonary Fibrosis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 244: Middle East 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 253: Iran 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 256: Iran 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 262: Israel 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 265: Israel 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 280: UAE 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 283: UAE 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • AFRICA
    • Pulmonary Fibrosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 298: Africa 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 301: Africa 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제